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use of transarterial radioembolization (TARE) with that of sorafenib in
the treatment of patients with intermediate or advanced hepatocel-
lular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer
staging system. Methods: Patient-level data were consecutively
recorded and collected at three oncology centers in Italy. A propensity
score matching was performed to compare patients with similar
clinical characteristics who underwent TARE or sorafenib treatment.
Clinical data from the matched cohorts were used to populate a
Markov model to project, on a lifetime horizon, life years, quality-
adjusted life years, and economic outcomes associated with TARE and
sorafenib for both intermediate and advanced HCC stages. Results:
Starting from data covering 389 and 241 patients who underwent
TARE and sorafenib treatment, respectively, the propensity score
matching yielded a total of 308 matched patients. For intermediate-
stage patients, the model estimated for TARE versus sorafenib an
incremental cost-utility ratio of €3,302/QALY (incremental cost-ee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
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an 20136, Italy.effectiveness ratio of €1,865 per life year gained), whereas for patients
in advanced stage TARE dominated (lower costs and greater health
improvements) compared with sorafenib. Conclusions: From an
Italian health care service perspective, TARE could be a cost-
effective strategy in comparison with sorafenib for patients with
intermediate or advanced HCC. The results from forthcoming
randomized controlled trials comparing TARE with sorafenib will be
able to conﬁrm or reject the validity of this preliminary evaluation. In
the meantime, decision makers can use these results to control and
coordinate the diffusion of the technology.
Keywords: cost-effectiveness, hepatocellular carcinoma, sorafenib,
TARE.
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Liver cancer is the ﬁfth most common cancer in men and the
ninth in women, representing the second most common cause of
cancer-related deaths in the world. The highest incidence of liver
cancer has been reported for sub-Saharan Africa and Southeast
Asia, and the incidence in some of these countries is 10 times
higher than reported for United States and Europe [1]. Prognosis
of liver cancer is very poor with a mortality-to-incidence ratio
of 0.95.
Hepatocellular carcinoma (HCC) represents approximately
75% of primary liver cancers and is a major global health
problem. The incidence of HCC increases progressively with
age, reaching a peak at 70 years [2].
Clinical guidelines [3–5] support surveillance, diagnostic, and
treatment practice for the management of patients with HCC.
Disease status is deﬁned through the Barcelona Clinic LiverCancer (BCLC) classiﬁcation, which takes into account the size
and the extent of the primary tumor, liver function, and physio-
logical factors [6]. This staging system categorizes patients with
early (stage A), intermediate (stage B), advanced (stage C), or
terminal (stage D) HCC. There is a related treatment plan for each
stage, ranging from potentially curative therapies (e.g., resection
or transplant for early-stage patients) to best supportive care for
end-stage patients.
Interventional locoregional treatments are recommended for
nonsurgical patients in the intermediate HCC stage. These treat-
ments include intra-arterial transcatheter embolotherapies
through a wide range of devices. Systemic therapy is generally
recommended for advanced disease stage (BCLC-C), in which
therapies are used with the intention to improve survival and/or
maintain quality of life without curative intent.
Transarterial radioembolization (TARE), also known as selec-
tive internal radiation therapy, is a liver-directed therapyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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explicitly recommended, and is considered experimental, in HCC
clinical guidelines [3–5,7].
TARE plays a potentially leading role in treating advanced
HCC accompanied with portal vein thrombosis (PVT) involve-
ment, a clinically relevant scenario occurring in about 40% of
patients [8]. TARE is a microembolic procedure causing minimal
occlusion of hepatic arteries; therefore, it can be safely used in
patients with PVT without compromising blood ﬂow to the
hepatic parenchyma [9]. Macrovascular tumor invasion is a
shared contraindication to transplantation, ablation, and any
kind of chemoembolization technique [3,4]. Treatments for
patients with HCC accompanied with PVT are more limited than
for those without PVT. Transarterial chemoembolization (TACE)
is considered contraindicated in cases of PVT because of its high
embolic effect [8], and the alternative to TARE for patients with
PVT is only systemic therapy with sorafenib.
According to the latest release of the European Society for
Medical Oncology guidelines, TARE may therefore be competitive
with sorafenib in patients in the intermediate stage who failed
chemoembolization treatment or in advanced patients with PVT
with no extrahepatic spread and good liver function [5]. At
present in Italy this treatment is offered to about 4% of patients
with intermediate or advanced HCC [10,11].
The evidence that supports the use of TARE in HCC treatment
is mainly based on retrospective or prospective observational
studies [12–16], and no cost-effectiveness analyses have been
performed comparing the use of TARE with that of sorafenib for
the treatment of patients with HCC. Two randomized controlled
trials (RCTs) comparing TARE with sorafenib are ongoing at
present (YES-P: NCT01887717; SARAH: NCT01482442). Although
RCTs are the most universally accepted and robust experimental
designs to estimate treatment effects, they are often conducted
in highly selected populations and may lack external validity
[17,18]. Moreover, randomization is not always feasible because
of technical or ethical issues, such as insufﬁcient evidence
equipoise. In the meantime, however, real-world data are accru-
ing because of the diffusion of this innovative therapy in the
clinical practice.
The aim of the present study was to perform a cost-
effectiveness analysis comparing TARE with sorafenib in patients
with intermediate or advanced HCC using real-world clinical data
collected at three major Italian oncology centers. TARE is an
established and simultaneously experimental procedure used in
Italy for the treatment of intermediate and advanced HCC. The
unmet clinical needs for this patient group are substantial, and
this study can inform decision makers in Italy regionally and
nationally in due course.Methods
Target Population and Interventions
The study focused on patients with intermediate or advanced
HCC treated with TARE (which alongside the TARE procedure
includes a bundle of inpatient procedures including diagnostic
tests) or sorafenib (target dose, 800 mg/d).
Overall survival (OS) and progression-free survival (PFS), deﬁned
as the time from the start of the treatment to progression or
death, whichever occurred ﬁrst, were identiﬁed as the most
important health outcomes.
Patient-level data were prospectively collected from 2005 to
2015 at three oncology centers with the highest volume of TARE
procedure use in Italy (National Cancer Institute, Milan; Azienda
Ospedaliero-Universitaria Pisana, Pisa; and Azienda Ospedaliero-
Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna).Because data from the three centers referred to different index
years (Milan, 2007; Bologna, 2005; and Pisa, 2013), we compared
the OS and PFS of patients treated in the ﬁrst 2 years versus
patients treated in the following years to check that no learning
curve effect was present.
After the exclusion of patients with metastatic disease, early
or terminal disease stage, and patients with metastases, a quality
check was performed to assess incomplete clinical data (OS or
PFS), out-of-range values, and consistency of data (OS and PFS
greater than 0, OS greater than or equal to PFS) [19]. Available
data have been gathered and merged to build a new data set to
populate the cost-effectiveness model. To compare patients with
comparable prognostic factors in the TARE and sorafenib groups,
a one-to-one nearest neighbor propensity score matching (PSM)
procedure [20] was performed. Because a systematic literature
review [21] reported PVT, alpha-fetoprotein, Child-Pugh class,
and tumor size as the most robust predictors for survival for
patients with HCC, these patients’ characteristics and prognostic
factors were taken into account by the clinical advisors and the
modeling team. In particular, Child-Pugh score uses ﬁve clinical
measures of liver disease (total bilirubin, serum albumin, pro-
thrombin time, ascites, and hepatic encephalopathy) to classify
patients according to different expected survivals (at 2 years: A,
85%; B, 57%; and C, 35%) [22].
Child-Pugh score, PVT status, and a proxy for tumor size (i.e.,
number of nodules) were judged as the main prognostic factors to
be considered in the PSM. A second round of data ﬁltering was
performed excluding patients with incomplete data on the PSM
variables, and then a logit function of the probability of receiving
either treatment for a patient with these baseline characteristics
was built. According to Tandon and Garcia-Tsao [21], patients’
demographic characteristics were not included in the analysis.
Different simulations were made, varying the radius from
0.001 to 1, to ﬁnd an adequate balance between bias reduction
and common support size. Patients were further classiﬁed into
being in intermediate and advanced stages according to the BCLC
staging system to perform subgroup analyses. STATA 11 software
(StataCorp, College Station, TX) and the command psmatch2 [23]
were used to perform the PSM.
The Model
A Markov multistate model was selected for this economic
evaluation and developed to project lifetime health (life years
and quality-adjusted life years [QALYs]) and economic outcomes
associated with TARE and sorafenib strategies for both inter-
mediate and advanced HCC stages. Markov models are com-
monly used in economic evaluations for oncology treatments by
health technology assessment bodies internationally. The model
structure and problem formulation have been validated during
two consecutive focus group meetings by the clinical expert
group. In particular, in the ﬁrst one, an evaluation of face validity
of the model’s structure and problem formulation was con-
ducted, whereas during the second meeting a discussion on the
evidence used to populate the model and on the results obtained
was undertaken [24].
The health states in the implemented Markov model include
(Fig. 1) stable disease, disease progression, death for disease, and
death for other causes. In the intermediate stage, an additional
state was included to take into account the possibility of liver
transplantation. A hypothetical cohort of patients with HCC
starts the Markov process in the stable state, that is, with stable
HCC. Patients may stay in the stable state or, in case of disease
progression, may move to the progression state. Progressive
patients may remain in the progression state or may die from
the disease (the model assumes that death for disease affects
only progressive patients). Transition probabilities between
Fig. 1 – Markov model. The health states included are stable
disease, disease progression, and death. In the intermediate
stage, an additional state was included to take into account
the possibility of liver transplantation. A hypothetical cohort
of 68-year-old (i.e., mean age of the matched population)
patients with HCC enter the Markov process in the stable
state (i.e., with stable HCC). HCC, hepatocellular carcinoma.
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undergoing TARE or sorafenib treatment have been estimated
from the matched population. Different curve functions (i.e.,
Weibull, Gompertz, and exponential) have been ﬁtted for the
PFS curves emerging from the two matched cohorts according to
treatment strategy. The performance of the different ﬁttings was
assessed according to standard evaluation criteria (Bayesian
information criterion), and the relevant transition probability
was derived accordingly.
Transition probabilities from disease progression to death
were considered time-dependent and were calibrated to approx-
imate the Kaplan-Meier postprogression survival curves as meas-
ured by the area under the curve calculated on the matched
patient-level data.
Mortality rates were further adjusted for age and sex accord-
ing to Italian mortality tables (National Institute of Statistics) to
take into account deaths caused by other comorbidities (“death
for other causes” state).
For patients undergoing sorafenib treatment, a clinical assess-
ment is performed each month, and hence a 1-month Markov
cycle length was chosen for baseline analysis. To consider mean,
rather than median effects, a lifetime horizon was chosen [25].
The model was constructed using TreeAge software (TreeAge
Software, Inc., Williamstown, MA).
Health Care Resource Consumption and Costs
The model includes only direct health resource consumption
(direct costs) (Table 1) based on 2015 base-case values (expressed
in euros). Data on costs were obtained from diagnosis related
group (DRG) reimbursement rates and ofﬁcial tariffs from Lom-
bardy to reﬂect an Italian regional health care system perspective.
After discussions with the clinical expert group, the treatment
protocol for TARE was conﬁrmed. The treatment pathway pro-
ceeds from a ﬁrst oncology visit to a procedure simulation (DRG
203), laboratory examinations, and the treatment itself (DRG 409).
After 1 month, a follow-up oncology visit and laboratory exami-
nations are repeated, including an abdomen computerized
tomography (CT) scan. Such follow-ups are conducted every 3
months [26].
For sorafenib treatment, after the ﬁrst oncology visit and
laboratory examinations, sorafenib (112 cp 200 mg each, hospital
cost €3,536.17) is given monthly to each patient until disease
progression. A payment-by-result scheme is in place for sorafe-
nib in Italy, whereby for each nonresponder in the ﬁrst 2 months,the drug manufacturer is expected to cover reimbursement costs
up to a maximum of two packages). Therefore, an abdomen CT
scan is performed 2 months after sorafenib initiation to verify the
disease state classiﬁcation. Otherwise, follow-up is the same as
in TARE.
Subsequent treatments were identiﬁed from the available
cohort data and incorporated in the model. Best supportive care
included use of off-label drugs, systemic chemotherapy of vary-
ing dose, and duration, which were not considered in the model.
Liver decompensation was recognized by the clinical experts as
the most economically and clinically relevant adverse event
leading to hospitalization (DRG 464; see Table 1). Liver trans-
plantation costs were based on the DRG 408 tariff, whereas
lifetime costs after the intervention were derived from the
literature [27] and were estimated at €6,182 per year. Prices were
inﬂated to 2015 values using the Harmonised Index of Consumer
Prices (DatastreamTM, Thomson Reuters, New York, NY) for Italy.
Quality-of-Life Estimates
Health-related quality-of-life measures were not available in the
patient-level data set and hence a literature search was con-
ducted. The utility coefﬁcients for patients with HCC were
obtained from the Cost-Effectiveness Analysis Registry, a com-
prehensive database of more than 4000 cost-utility analyses on a
wide variety of diseases and treatments [28]. For each health
state considered in the model (stable disease, progression, and
liver transplantation) excluding death, utility coefﬁcients were
retrieved and an average value was derived. A summary of the
retrieved utilities and related mean values is presented in
Appendix Table 1 [29–45] in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2016.09.2397.
Baseline Analyses
Both incremental cost-effectiveness ratio (ICER) and incremental
cost-utility ratio (ICUR) of TARE versus sorafenib were calculated
by dividing the incremental cost by the incremental health
improvement. Life years, QALYs, and costs were discounted at
a 3.5% yearly rate [46]. Transition probabilities, costs, and utilities
were entered into the model along with a distribution: beta for
utilities and proportions of patients performing after treatments
and gamma for costs and number of TARE treatments (see
Appendix Table 2 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2016.09.2397). Deterministic and probabilis-
tic sensitivity analyses were performed to test the robustness of
the model. Univariate analyses were performed according to time
horizon, mean number of TARE procedures per patient, discount
rate, probability of liver transplantation, mean age of the cohort,
and price of a 112-cp pack of sorafenib excluding the pay-by-
result price.
Second-order Monte-Carlo simulations (10,000 iterations)
were conducted for intermediate and advanced stages to take
into account parameter variability as described in Appendix
Table 2 in Supplemental Materials and the resulting scatterplots
were plotted onto a cost-effectiveness plane.
Scenario Analyses
To investigate model structural uncertainty, different analyses
were performed. A scenario analysis was performed including the
cost of best supportive care and terminal care reported in the
literature for the Italian setting (€4,142 [2012] corresponding to
€4,192 [2015]) [47].
Another scenario analysis was performed including in the
model all registered events of grade III/IV experienced during the
treatment with TARE or sorafenib available from the subset of
patients (N ¼ 66) collected at Bologna Oncology Centre (Azienda
Table 1 – Costs used in the model.
Exam/procedure/DRG Code Cost (€) Source
CT scan (abdomen)* 88.01.5 137.23 Regional Healthcare Service price list
First visit 89.7B.6 22.50 Regional Healthcare Service price list
Control visit* 89.01.F 17.90 Regional Healthcare Service price list
Blood cell count* 90.62.2 4.05 Regional Healthcare Service price list
Creatinine* 90.16.3 1.70 Regional Healthcare Service price list
Sodium* 90.40.4 1.70 Regional Healthcare Service price list
Potassium* 90.37.4 1.70 Regional Healthcare Service price list
Calcium* 90.11.4 1.70 Regional Healthcare Service price list
Prothrombin time* 90.75.4 2.60 Regional Healthcare Service price list
Albumin* 90.05.1 2.90 Regional Healthcare Service price list
Bilirubin* 90.10.4 1.55 Regional Healthcare Service price list
Alpha-fetoprotein* 90.05.5 11.05 Regional Healthcare Service price list
Alanine amino transferase (gpt)* 90.04.5 1.70 Regional Healthcare Service price list
Gamma-glutamyl transpeptidase* 90.25.5 1.70 Regional Healthcare Service price list
Alkaline phosphatase* 90.23.5 1.70 Regional Healthcare Service price list
TARE simulation 203 4,052 Regional DRG reimbursement
TARE 409 9,510 Regional DRG reimbursement
TACE 203 4,052 Regional DRG reimbursement
RFA/PEI or liver resection 192 7,549 Regional DRG reimbursement
Radiotherapy 409 4,041 Regional DRG reimbursement
Hospitalization for liver decompensation 464 1,688 Regional DRG reimbursement
Liver transplantation 480 68,027 Regional DRG reimbursement
Liver transplantation (yearly cost after intervention) 6,182 [27]
CT, computed tomography; DRG, diagnosis related group; gpt, glutamic pyruvic transaminase; PEI, percutaneous ethanol injection; RFA,
radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.
* Every 3 mo.
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Other analyses were performed excluding death from causes
other than the disease, and considering a different model
structure that distinguishes patients according to the best radio-
logical response (stable disease, complete or partial response
according to mRECIST criteria [48]). Because no speciﬁc utility
weights were found in the literature to distinguish among the
cited states, we considered the distribution of values obtained
from the different studies (as reported in Appendix Table 1 in
Supplemental Materials) and we chose 25th and 75th percentiles
to estimate utility values for stable disease (0.37) and complete/
partial response (0.7), respectively. Further information is pre-
sented in the Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2016.09.2397.Results
Target Population
Data covering 389 patients who underwent TARE and 241 patients
who underwent sorafenib treatment were retrieved. Out of these
patients, 43 (6%) and 24 (4%) patients, respectively, were excluded
who presented with either metastatic disease or a disease stage
outside the scope of this analysis (e.g., BCLC-A or BCLC-D). Sixty-four
patients (10%) with incomplete survival data were excluded, and two
patients were excluded because of missing data on the main
parameters (presence of PVT and number of nodules).
PSM was performed on 497 patients by varying the caliper
radius. For values less than or equal to 0.2, the PSM yielded a
sample of 308 patients with identical clinical characteristics
(100% reduction bias on all the variables), whereas for valueshigher than 0.2 the sample comprised a higher number of
patients but with a bias reduction less than 100% for all the
considered variables (see Appendix in Supplemental Materials for
further details).
The ﬁnal database resulted in 308 patients (154 TARE and 154
sorafenib) with matched clinical characteristics. Because the
small difference in mean age between the matched cohorts
seemed not to inﬂuence the clinical outcomes, a mean age of
68 years was considered for both cohorts of patients.
A greater number of patients in the TARE cohort (71%)
belonged to the intermediate stage compared with those in the
sorafenib cohort (49%). A summary of the patients’ characteristics
before and after the matching is presented in Table 2.
In the ﬁnal cohorts, the mean survivals obtained for patients
in the intermediate stage (BCLC-B) undergoing TARE and sorafe-
nib treatment were 24 (median 18.5) and 18.4 (median 13)
months, respectively. These values decreased respectively to
14.9 (median 11.2) and 16.1 (median 11.3) months for patients in
the advanced stage (BCLC-C).
Curve Fitting
PFS curves for TARE strategy were better approximated using
Weibull and Gompertz functions for intermediate and advanced
stages, respectively. PFS curves for sorafenib strategy (intermedi-
ate and advanced stages) were better approximated by exponen-
tial functions (see Appendix Figure 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2016.09.2397). For each
survival curve, we veriﬁed, with a simulation of the same
duration of the cohort follow-up, that the difference between
the average survival calculated from patient-level data and the
average survival estimated by the model was less than 10 days
for each event of interest (death or progression) for each disease
Table 2 – Characteristics of unmatched and matched treatment groups.
Characteristics Unmatched cohorts P Matched cohorts P Test
TARE Sorafenib TARE Sorafenib
Mean age (y) 66 70 o0.001 67 70 0.02 t test
Males 82.1% 78.5% 0.3 84.4% 76% 0.6 Chi-square
Multinodular* 70.1% 86.6% o0.001 86.4% 86.4% 1 Chi-square
PVT* 61.7% 25.6% o0.001 24% 24% 1 Chi-square
Child A* 92.4% 92.3% 0.97 95.5% 95.5% 1 Chi-square
PSM, propensity score matching; PVT, portal venous thrombosis; TARE, transarterial radioembolization.
* Variable selected for PSM.
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Table 3 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2016.09.2397.
Baseline Results
The mean number of TARE treatments per patient was 1.1 and
1.02 for intermediate and advanced stages, respectively, and the
mean duration of sorafenib treatment was 7.5 and 8.1 months for
intermediate and advanced stages, respectively.
Subsequent treatments for TARE patients in intermediate
stage were sorafenib (30.3%), TACE (18.3%), radiofrequency abla-
tion (RFA)/resection (5.5%), and liver transplantation (3.7%). For
TARE patients in advance stage, subsequent treatments were
sorafenib (20%), TACE (2.2%), and radiotherapy (2.2%). After treat-
ment with sorafenib, subsequent treatments for patients in
intermediate stage were TACE (6.6%) and RFA/percutaneous
ethanol injection (10.5%), whereas patients in advanced stage
underwent TACE (2.6%) or RFA (1.3%).
Adverse events clinical data showed that 19.4% and 43% of
TARE patients in intermediate and advanced stages, respectively,
developed liver decompensation. For the sorafenib cohort, 17.4%
and 31% patients in intermediate and advanced stages, respec-
tively, developed liver decompensation.
Average life expectancy (mean) in the intermediate stage was
estimated to be 2.531 (1.178 QALYs) and 1.575 (0.638 QALYs) years
for patients undergoing TARE and sorafenib treatment, respec-
tively. The mean costs per patient were estimated to be €31,071
and €29,289 for patients undergoing TARE and sorafenib regimen,
respectively. In intermediate-stage patients, TARE resulted in an
ICUR of €3,302/QALY (ICER €1,865 per life year gained).
Average life expectancy in the advanced stage was estimated
to be 1.445 (0.639 QALYs) and 1.306 (0.568 QALYs) years, respec-
tively, for patients undergoing TARE and sorafenib regimen. The
estimated mean costs per patient were €21,961 and €30,750 for
patients undergoing TARE and sorafenib treatment, respectively.
In patients in advanced stage, TARE dominated (lower costs and
greater health improvements) compared with sorafenib.
The model results for the two scenarios are presented in
Table 3.Table 3 – Summary of the model results.
Disease
stage
Strategy Cost
(€)
Δ Cost
(€)
LY Δ
Intermediate TARE 31,071 1,782 2.531 0
Sorafenib 29,289 1.575
Advanced TARE 21,961 1.445 0
Sorafenib 30,750 8,788 1.306
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utilityAnalyses
Table 4 presents the results of one-way sensitivity analyses
performed on the main model parameters. Variation in the mean
number of TARE procedures used per patient (from one to three)
can greatly inﬂuence the ICER, most signiﬁcantly for patients in
the advanced stage.
Variations in patient age, monthly probability of liver trans-
plantation, and discount rate did not inﬂuence the ICUR for
advanced disease stage. In intermediate-stage patients, a
monthly probability of liver transplantation lower than 0.0021,
in the ﬁrst 6 years, showed that TARE could be a dominant
strategy. In the same group of patients, an age variation from 60
to 80 years showed a decreasing ICUR. A similar trend was
observed when discount rates were increased from 0% to 10%.
With regard to sorafenib costs, for advanced disease stage
patients a price reduction of 50% could lead to an ICUR of around
€37,000/QALY; for intermediate-stage patients, such a reduction
could lead to a more limited increase in the ICUR (€20,529/QALY).
Testing sorafenib price without the pay-by-result scheme showed
a reduction in only the ICUR for intermediate-stage patients,
whereas for advanced stage of disease TARE still remained
dominant.
The scenario analysis performed including the cost of best
supportive care for terminally ill patients yielded for TARE life-
time costs of €34,627 and €25,804 for intermediate and advanced
stages, respectively. For sorafenib treatment, the values reported
were €33,132 and €34,661, respectively. On the basis of these data,
in intermediate-stage patients, the ICUR of TARE versus that of
sorafenib decreased to €2,771 in comparison with the baseline
analysis, whereas TARE was conﬁrmed a dominant strategy for
advanced disease stage patients.
With regard to the analysis on severe adverse events (grade
III/IV), patients undergoing TARE experienced cholecystitis
(6.7% intermediate stage, about 50% advanced stage), whereas
intermediate-stage patients undergoing sorafenib treatment
mainly experienced metabolic disorders (10.3%), fatigue, asthe-
nia, erythema, and hand-foot syndrome (3.4% each). Advanced
disease stage patients undergoing sorafenib treatment experi-
enced pain (5%), fatigue (15%), and nausea (10%). After theLY QALYs ΔQALYs ICER
(€/LY)
ICUR
(€/QALY)
.956 1.178 0.540 1,865 3,302
0.638
.139 0.639 0.071 Dominant Dominant
0.568
ratio; LY, life year; QALY, quality-adjusted life year.
Table 4 – One-way sensitivity analyses of the cost-
effectiveness of TARE vs. sorafenib (results are
expressed as cost per QALY gained [discounted]).
ICUR
Model Parameter Intermediate
stage
Advanced stage
Baseline €3,302 TARE dominant
Time horizon (y)
1 TARE dominant Sorafenib vs. TARE
€322,488
2 TARE dominant Sorafenib vs. TARE
€238,642
4 TARE dominant Sorafenib vs. TARE
€313,604
6 TARE dominant Sorafenib vs. TARE
€840,495
8 TARE dominant TARE dominant
10 €1,067 TARE dominant
15 €2,649 TARE dominant
20 €3,116 TARE dominant
Mean number of TARE per patient
1 €744 TARE dominant
1.4 €10,978 TARE dominant
1.8 €21,212 €27,776
2.2 €31,447 €105,190
2.6 €41,681 €182,605
3 €51,915 €260,020
Patient age (y)
60 €4,315 TARE dominant
65 €3,772 TARE dominant
70 €2,897 TARE dominant
75 €1,524 TARE dominant
80 TARE dominant TARE dominant
Monthly probability of liver transplant (ﬁrst 6 y)
0 TARE dominant TARE dominant
0.0007 TARE dominant TARE dominant
0.00175 TARE dominant TARE dominant
0.0028 €1,952 TARE dominant
0.0035 €3,302 TARE dominant
Sorafenib cost
50% (€1,893) €20,529 €37,061
40% (€2,272) €17,082 €4,996
30% (€2,651) €13,635 TARE dominant
20% (€3,030) €10,188 TARE dominant
10% (€3,408) €6,749 TARE dominant
þ10% (€4,166) TARE dominant TARE dominant
No pay-by-result
scheme
€60 TARE dominant
Discount rate (%)
0 €4,956 TARE dominant
1 €4,496 TARE dominant
2 €4,024 TARE dominant
3 €3,545 TARE dominant
5 €2,570 TARE dominant
10 €151 TARE dominant
QALY, quality-adjusted life year; ICUR, incremental cost-utility
ratio; TARE, transarterial radioembolization.
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(for detailed data, see Appendix Table 4 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2016.09.2397), for TARE
the model yielded lifetime costs of €31,149 and €22,547 for
intermediate and advanced stages, respectively, whereascorresponding lifetime costs for sorafenib treatment were
€29,747 and €31,194, respectively. In intermediate-stage patients,
the ICUR was €2,599, lower than the one reported for the base-case
analysis. For advanced disease stage patients, TARE was con-
ﬁrmed a dominant strategy.
Concerning structural uncertainties, excluding death from
causes other than HCC in the model yielded an ICUR of €5,637
for TARE versus sorafenib in intermediate-stage patients; for
advanced disease stage patients, TARE remained the dominant
strategy (see detailed results in Appendix Table 5 in Supplemen-
tal Materials found at http://dx.doi.org/10.1016/j.jval.2016.09.
2397).
The analysis performed considering a different model struc-
ture allowing for different utility weights for treatment response
states showed the stability of the results obtained in the baseline
analysis (see Appendix in Supplemental Materials for detailed
results).
The plots of discounted incremental costs versus incremental
QALYs obtained from the Monte-Carlo simulations are shown in
Figure 2 (A: intermediate stage; B: advanced stage). Dotted
lines represent a theoretical cost-effectiveness threshold of
€50,000/QALY; 99.8% and 98% of points lie below this line for
intermediate and advanced stages, respectively. A theoretical
cost-effectiveness threshold of £30,000/QALY (€38,500) shows
similar results: 99.2% and 98.2% for intermediate and advanced
stages, respectively.Discussion
TARE has emerged as a locoregional treatment option for patients
with unresectable HCC. It is a sophisticated therapy, available
only in specialized centers, and requiring intervention from a
multidisciplinary team (including interventional radiology,
nuclear medicine, surgery, hepatology, and medical oncology)
[49]. TARE treatment may be competitive with sorafenib, an oral
antineoplastic agent, used in intermediate-stage patients who
failed chemoembolization or advanced disease stage patients
with or without PVT, with no extrahepatic spread and good liver
function. Although TARE showed promising clinical efﬁcacy with
a good safety proﬁle in phase II studies and registries [12], the use
of this treatment is not formally recommended in clinical guide-
lines at present.
Large RCTs comparing TARE with sorafenib are ongoing but
no clinical results have been published to date. TARE uptake in
clinical practice is growing in Italy and in other countries [50].
Because the diffusion of medical devices generally precedes
experimental evidence, decision makers such as physicians and
health care organizations are already familiar with the technol-
ogy before comparative clinical evidence is available. The use of
real-world data to support decision making is therefore of great
interest [51]. This issue is common across medical devices and
has been observed for other technologies [52].
The present study aimed to evaluate the cost-effectiveness of
TARE versus sorafenib to assess the value of presently available
treatment options in clinical practice.
The analysis was performed using observational real-world
data from three major oncology centers in Italy. Life expectancies
derived from this cohort are comparable with those reported in
the literature for TARE, for intermediate stage, ranging from 3.6 to
18.4 months, and for advanced stage, ranging from 6.4 to 13.8
months [53]. Similarly for sorafenib treatment, life expectancies
are comparable with the outcomes of a subgroup analysis of the
Sorafenib Hepatocellular carcinoma Assessment Randomized
Protocol (SHARP) trial [54], which reported median survivals of
9.7 and 14.5 months for intermediate and advanced stages,
respectively.
Fig. 2 – Incremental costs vs. incremental QALYs for intermediate (A) and advanced (B) HCC stages. HCC, hepatocellular
carcinoma; QALYs, quality-adjusted life years.
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care service perspective TARE could be a cost-effective strategy
compared with sorafenib treatment for patients in intermediate or
advanced HCC stage. Sensitivity and scenario analyses showed the
robustness of the baseline results: only variations in the time
horizon and in the number of TARE treatments per patient could
lead to an ICUR of more than €50,000/QALY gained. The number of
TARE treatments per patient, however, is unlikely to be greater than
1.5. Furthermore, probabilistic sensitivity analyses conﬁrmed the
results, with most of the simulations (almost all for intermediate
stage) lying below the commonly accepted ICUR threshold repre-
senting value for money.
In the literature, a paucity of studies present a cost-
effectiveness analysis comparing TARE with sorafenib for the
treatment of patients with HCC. To our knowledge, only Chaplin
et al. [55] published an abstract reporting results for the UK
setting. The study, based on published evidences, showed that
TARE can be considered a dominant strategy in comparison with
sorafenib (TARE £21,441 vs. sorafenib £34,050; QALY gain of 0.27
for TARE). Other studies estimated the costs related to TARE or
sorafenib for patients with HCC, with few of them in the Italian
setting. From the Italian health care service perspective, one
study [47] reported total costs of €24,224 and €14,841 for sorafenib
treatment for intermediate and advanced stages, respectively.
Anyway, the time horizon was limited to 5 years and the under-
lying model did not include the management of side effects and
following treatments. Another study [45] reported a cost of
€22,500 from the Italian health care service perspective for a
treatment with sorafenib as a bridge to liver transplantation. In
this case, the cost accounted for 5 months of treatment consid-
ering 600 mg per day. A more recent study [11] investigated the
costs for TARE and sorafenib treatment in patients with HCC
from the hospital perspective, reporting costs of €26,106 and
€12,215, respectively. The analysis, based on a survey, considered
the costs for professionals, drugs, consumables, and overheads
only for ﬁrst-line treatments (6.08 months for sorafenib and 1.5
TARE sessions per patient).
The present study has a number of limitations. First, the
clinical effectiveness was derived on the matched databases with
a limited number of patients in selected major oncology centers,
and therefore the generalizability of the real-world patient data
collected to the broader Italian HCC population could not be
tested. Moreover, in propensity score estimation, considering
only a few covariates may alter the estimation and interpretation
of other hidden nonobservable covariates, and hence the general-
izability of the results has to be treated cautiously [56].
Second, the model lifetime results are greatly inﬂuenced by
the survival curve extrapolations derived from non-RCT data.Continuous monitoring and recording of survival data in this
population will be useful to conﬁrm the assumptions made, not
least once major RCTs report survival data.
Third, health care resource consumption was retrieved from
the clinical data only for cancer-related therapies (i.e., number of
TARE treatments and sorafenib treatment duration), whereas for
the follow-up period the schedule for visits and examinations
was applied. This approach could have led to differences between
the estimated and actual health care resource consumption.
Fourth, with regard to adverse events, because of the lack of
reported data, liver decompensation was considered as the main
consequence due to TARE or sorafenib; anyway, the scenario
analysis conducted considering other severe side effects experi-
enced by a subset of patients conﬁrmed that TARE can be
considered a cost-effective treatment in comparison with sor-
afenib for patients with HCC. Frequencies of severe side effects
experienced by advanced disease stage patients treated with
sorafenib (30%) resulted in line with the ones presented by the
GIDEON study [57], which reported grade III/IV adverse events in
29% of cases (BCLC-C group). For intermediate-stage patients,
severe adverse events frequency used in the model (24%) can be
considered a conservative estimate of the total effect as reported
by the cited study (34%).
Fifth, best supportive care and terminal care were not con-
sidered in the base-case model but may have a signiﬁcant impact
on total costs of treatment care; anyway, the scenario analysis
performed considering cost data from an Italian study [47]
conﬁrmed the conclusions of the baseline model.
Finally, survivals and resource consumption related to
patients treated with new technologies, such as TARE, may be
inﬂuenced by the underlying learning curve related to the
experience of the operators. Nevertheless, a preliminary analysis
performed comparing survival data before and after the ﬁrst 2
years from the introduction of the new technology did not show
any signiﬁcant effect.Conclusions
TARE seems to be a valid treatment option for patients in
intermediate and advanced HCC stages. The trial results from
forthcoming RCTs comparing TARE with sorafenib will increase
the clinical evidence qualitatively to conﬁrm or reject the validity
of this preliminary evaluation. In the meantime, decision makers
can make use of these results to issue preliminary coverage
recommendations, for approval in deﬁned target patient popula-
tions, or using conditional approval methods.
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